1.Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea.
Byung Sup KIM ; Ho Jun SEOL ; Do Hyun NAM ; Chul Kee PARK ; Il Han KIM ; Tae Min KIM ; Jeong Hoon KIM ; Young Hyun CHO ; Sang Min YOON ; Jong Hee CHANG ; Seok Gu KANG ; Eui Hyun KIM ; Chang Ok SUH ; Tae Young JUNG ; Kyung Hwa LEE ; Chae Yong KIM ; In Ah KIM ; Chang Ki HONG ; Heon YOO ; Jin Hee KIM ; Shin Hyuk KANG ; Min Kyu KANG ; Eun Young KIM ; Sun Hwan KIM ; Dong Sup CHUNG ; Sun Chul HWANG ; Joon Ho SONG ; Sung Jin CHO ; Sun Il LEE ; Youn Soo LEE ; Kook Jin AHN ; Se Hoon KIM ; Do Hun LIM ; Ho Shin GWAK ; Se Hoon LEE ; Yong Kil HONG
Cancer Research and Treatment 2017;49(1):193-203
PURPOSE: The purpose of this study was to investigate the feasibility and survival benefits of combined treatment with radiotherapy and adjuvant temozolomide (TMZ) in a Korean sample. MATERIALS AND METHODS: A total of 750 Korean patients with histologically confirmed glioblastoma multiforme, who received concurrent chemoradiotherapy with TMZ (CCRT) and adjuvant TMZ from January 2006 until June 2011, were analyzed retrospectively. RESULTS: After the first operation, a gross total resection (GTR), subtotal resection (STR), partial resection (PR), biopsy alone were achieved in 388 (51.7%), 159 (21.2%), 96 (12.8%), and 107 (14.3%) patients, respectively. The methylation status of O6-methylguanine-DNA methyltransferase (MGMT) was reviewed retrospectively in 217 patients. The median follow-up period was 16.3 months and the median overall survival (OS) was 17.5 months. The actuarial survival rates at the 1-, 3-, and 5-year OS were 72.1%, 21.0%, and 9.0%, respectively. The median progression-free survival (PFS) was 10.1 months, and the actuarial PFS at 1-, 3-, and 5-year PFS were 42.2%, 13.0%, and 7.8%, respectively. The patients who received GTR showed a significantly longer OS and PFS than those who received STR, PR, or biopsy alone, regardless of the methylation status of the MGMT promoter. Patients with a methylated MGMT promoter also showed a significantly longer OS and PFS than those with an unmethylated MGMT promoter. Patients who received more than six cycles of adjuvant TMZ had a longer OS and PFS than those who received six or fewer cycles. Hematologic toxicity of grade 3 or 4 was observed in 8.4% of patients during the CCRT period and in 10.2% during the adjuvant TMZ period. CONCLUSION: Patients treated with CCRT followed by adjuvant TMZ had more favorable survival rates and tolerable toxicity than those who did not undergo this treatment.
Biopsy
;
Chemoradiotherapy*
;
Disease-Free Survival
;
Follow-Up Studies
;
Glioblastoma*
;
Humans
;
Korea*
;
Methylation
;
Radiotherapy
;
Retrospective Studies*
;
Survival Rate
2.Current Guidelines on the Management of Dyslipidemia.
Yunjeong CHOI ; Song LEE ; Ju Young KIM ; Kyung Eun LEE
Korean Journal of Clinical Pharmacy 2017;27(4):276-283
OBJECTIVE: Dyslipidemia is recognized as a prominent risk factor for cardiovascular and cerebrovascular diseases but it is manageable through therapeutic and lifestyle intervention. Interpreting the latest guidelines is essential for an application of recommendation from guidelines into clinical practice. Therefore, this study aimed to compare the most recent guidelines on dyslipidemia treatment recommendations in Korea and USA. METHODS: This study analyzed and compared 2015 Korean guidelines for the management of dyslipidemia, 2013 American College of Cardiology/American Heart Association (ACC/AHA) guideline and 2016 supportive guidelines from ACC. RESULTS: A comparison was made focused on the following: target patients based on cardiovascular risk assessment, target goal, and treatment strategies including statin and non-statin therapies. Four target patient groups by risk were suggested in 2015 Korean guideline and cardiovascular risk factors were also considered for initiation of lipid lowering therapy. Titrated statin regimen was recommended by Korean guideline to reach LDL cholesterol and non-HDL cholesterol target level. In 2013 ACC/AHA guideline, four statin benefit group was introduced considering ASCVD risk and high intensity statin or intermediate intensity statin use were recommended without dose titration. 2016 update was to support non-statin therapy based on updated evidence and new consideration of ezetimibe, PCSK9-inhibitor and bile acid sequestrant was brought up. CONCLUSION: Guidelines are continuously updating as new and important clinical data are constantly released along with the advent of newly approved drugs for lipid disorder. This article provides resources that facilitates uptake of these recommendations into clinical practice.
3.Antitumor Effect of KX-01 through Inhibiting Src Family Kinases and Mitosis.
Seongyeong KIM ; Ahrum MIN ; Kyung Hun LEE ; Yaewon YANG ; Tae Yong KIM ; Jee Min LIM ; So Jung PARK ; Hyun Jin NAM ; Jung Eun KIM ; Sang Hyun SONG ; Sae Won HAN ; Do Youn OH ; Jee Hyun KIM ; Tae You KIM ; David HANGAUER ; Johnson Yiu Nam LAU ; Kyongok IM ; Dong Soon LEE ; Yung Jue BANG ; Seock Ah IM
Cancer Research and Treatment 2017;49(3):643-655
PURPOSE: KX-01 is a novel dual inhibitor of Src and tubulin. Unlike previous Src inhibitors that failed to show clinical benefit during treatment of breast cancer, KX-01 can potentially overcome the therapeutic limitations of current Src inhibitors through inhibition of both Src and tubulin. The present study further evaluates the activity and mechanism of KX-01 in vitro and in vivo. MATERIALS AND METHODS: The antitumor effect of KX-01 in triple negative breast cancer (TNBC) cell lines was determined by MTT assay. Wound healing and immunofluorescence assays were performed to evaluate the action mechanisms of KX-01. Changes in the cell cycle and molecular changes induced by KX-01 were also evaluated. A MDA-MB-231 mouse xenograft model was used to demonstrate the in vivo effects. RESULTS: KX-01 effectively inhibited the growth of breast cancer cell lines. The expression of phospho-Src and proliferative-signaling molecules were down-regulated in KX-01-sensitive TNBC cell lines. In addition, migration inhibition was observed by wound healing assay. KX-01-induced G2/M cell cycle arrest and increased the aneuploid cell population in KX-01-sensitive cell lines. Multi-nucleated cells were significantly increased after KX-01 treatment. Furthermore, KX-01 effectively delayed tumor growth in a MDA-MB-231 mouse xenograft model. CONCLUSION: KX-01 effectively inhibited cell growth and migration of TNBC cells. Moreover, this study demonstrated that KX-01 showed antitumor effects through the inhibition of Src signaling and the induction of mitotic catastrophe. The antitumor effects of KX-01 were also demonstrated in vivo using a mouse xenograft model.
Aneuploidy
;
Animals
;
Breast Neoplasms
;
Cell Cycle
;
Cell Cycle Checkpoints
;
Cell Line
;
Fluorescent Antibody Technique
;
Heterografts
;
In Vitro Techniques
;
Mice
;
Microtubules
;
Mitosis*
;
src-Family Kinases*
;
Triple Negative Breast Neoplasms
;
Tubulin
;
Wound Healing
4.Practice guidelines for management of cervical cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement.
Myong Cheol LIM ; Maria LEE ; Seung Hyuk SHIM ; Eun Ji NAM ; Jung Yun LEE ; Hyun Jung KIM ; Yoo Young LEE ; Kwang Beom LEE ; Jeong Yeol PARK ; Yun Hwan KIM ; Kyung Do KI ; Yong Jung SONG ; Hyun Hoon CHUNG ; Sunghoon KIM ; Jeong Won LEE ; Jae Weon KIM ; Duk Soo BAE ; Jong Min LEE
Journal of Gynecologic Oncology 2017;28(3):e22-
Clinical practice guidelines for gynecologic cancers have been developed by academic society from several countries. Each guideline reflected their own insurance system and unique medical environment, based on the published evidence. The Korean Society of Gynecologic Oncology (KSGO) published the first edition of practice guidelines for gynecologic cancer treatment in late 2006; the second edition was released in July 2010 as an evidence-based recommendation. The Guidelines Revision Committee was established in 2015 and decided to develop the third edition of the guidelines in an advanced format based on evidence-based medicine, embracing up-to-date clinical trials and qualified Korean data. These guidelines cover strategies for diagnosis and treatment of primary and recurrent cervical cancer. The committee members and many gynecologic oncologists derived key questions through discussions, and a number of relevant scientific literature were reviewed in advance. Recommendations for each specific question were developed by the consensus conference, and they are summarized here, along with the details. The objective of these practice guidelines is to establish standard policies on issues in clinical practice related to the management in cervical cancer based on the results in published papers to date and the consensus of experts as a KSGO Consensus Statement.
Committee Membership
;
Consensus*
;
Diagnosis
;
Drug Therapy
;
Evidence-Based Medicine
;
Insurance
;
Korea*
;
Uterine Cervical Neoplasms*
5.Relationship between age at last delivery and age at menopause: The Korea National Health and Nutrition Examination Survey.
Yeun Joo SHIN ; Ji Yong SONG ; Min Jeong KIM ; Jeong In CHOI ; Kyung Do HAN ; Hae Nam LEE
Obstetrics & Gynecology Science 2017;60(4):362-368
OBJECTIVE: We used data from the 2010 to 2012 Korean National Health and Nutrition Examination Surveys to investigate whether the age at menopause is related to age at last delivery. METHODS: This was a cross-sectional study of the data for 714 women who became menopausal within the 3 years preceding the Korean National Health and Nutrition Examination Survey. RESULTS: Smoking, exercise, drink, educational level, and income were adjusted in model 1, and the mean ages at menopause were 50.5±0.3, 51.2±0.2, 51.2±0.3, and 50.2±0.4 years for women with <25, ≥25 and <30, ≥30 and <35, ≥35 years age at last delivery, respectively (P=0.049). Smoking, exercise, drink, educational level, income, age at first delivery, age at last delivery, and gravidity were adjusted in model 2, and the respective mean ages at menopause were 50.5±0.5, 50.7±0.4, 50.3±0.4, and 49.2±0.5 years (P=0.03). In both models, older age at last delivery showed higher age at menopause compared with women with younger age at last delivery. CONCLUSION: Korean women with older age at last delivery were associated with younger age at menopause. Increased number of pregnancies was related to older age at menopause.
Cross-Sectional Studies
;
Female
;
Gravidity
;
Humans
;
Korea*
;
Menopause*
;
Nutrition Surveys*
;
Pregnancy
;
Smoke
;
Smoking
6.Diagnostic Yield and Clinical Impact of Video Capsule Endoscopy in Patients with Chronic Diarrhea: A Korean Multicenter CAPENTRY Study.
Hyun Joo SONG ; Jeong Seop MOON ; Seong Ran JEON ; Jin Oh KIM ; Jinsu KIM ; Dae Young CHEUNG ; Myung Gyu CHOI ; Yun Jeong LIM ; Ki Nam SHIM ; Byong Duk YE ; Jae Hee CHEON ; Cheol Hee PARK ; Hyun Soo KIM ; Ji Hyun KIM ; Dong Kyung CHANG ; Jae Hyuk DO ; Kyeong Ok KIM ; Byung Ik JANG ; Sung Jae SHIN
Gut and Liver 2017;11(2):253-260
BACKGROUND/AIMS: In some cases, chronic diarrhea is unexplained, and small bowel disorders may be one of the causes. The aim of this study was to assess the diagnostic yield and clinical impact of video capsule endoscopy (VCE) in patients with chronic diarrhea. METHODS: We retrospectively analyzed records from October 2002 to August 2013 in the VCE nationwide database registry (n=2,964). Ninety-one patients from 15 medical centers (60 males and 31 females; mean age, 47±19 years) were evaluated for VCE as a result of chronic diarrhea. RESULTS: The duration of chronic diarrhea was 8.3±14.7 months. The positive diagnostic yield of VCE was 42.9% (39/91). However, 15.4% (14/91) exhibited an inconsistent result, and 41.8% (38/91) were negative. Abnormal findings consistent with chronic diarrhea included erosions/aphthous ulcers (19.8%), ulcers (17.6%), mucosal erythema (3.3%), edema (1.1%), and luminal narrowing (1.1%). The most common diagnoses were functional diarrhea associated with irritable bowel syndrome in 37 patients (40.7%) and Crohn’s disease in 18 patients (19.8%). After VCE examination, the diagnosis was changed in 34.1% of the patients (31/91). Hematochezia (odds ratio [OR], 8.802; 95% confidence interval [CI], 2.126 to 36.441) and hypoalbuminemia (OR, 4.811; 95% CI, 1.241 to 18.655) are predictive factors of a positive diagnostic yield. CONCLUSIONS: VCE had a favorable diagnostic yield and clinical impact on the management of patients with chronic diarrhea.
Capsule Endoscopy*
;
Diagnosis
;
Diarrhea*
;
Edema
;
Erythema
;
Female
;
Gastrointestinal Hemorrhage
;
Humans
;
Hypoalbuminemia
;
Irritable Bowel Syndrome
;
Male
;
Phenobarbital
;
Retrospective Studies
;
Ulcer
7.Crotonis Fructus Extract Inhibits 12-O-Tetradecanoylphorbol-13-Acetate-Induced Expression of Matrix Metalloproteinase-9 via the Activator Protein-1 Pathway in MCF-7 Cells.
Hyun Kyung SONG ; Guem San LEE ; Sueng Hyuk PARK ; Eun Mi NOH ; Jeong Mi KIM ; Do Gon RYU ; Sung Hoo JUNG ; Hyun Jo YOUN ; Young Rae LEE ; Kang Beom KWON
Journal of Breast Cancer 2017;20(3):234-239
PURPOSE: Metastatic cancers spread from the primary site of origin to other parts of the body. Matrix metalloproteinase-9 (MMP-9) is essential in metastatic cancers owing to its major role in cancer cell invasion. Crotonis fructus (CF), the mature fruits of Croton tiglium L., have been used for the treatment of gastrointestinal disturbance in Asia. In this study, the effect of the ethanol extract of CF (CFE) on MMP-9 activity and the invasion of 12-O-tetradecanoylphorbol-13-acetate (TPA)-treated MCF-7 cells was examined. METHODS: The cell viability was evaluated using the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay. The expression of MMP-9 was examined by Western blotting, zymography, and real-time polymerase chain reaction. An electrophoretic mobility gel shift assay was performed to detect activator protein-1 (AP-1) DNA binding activity and cell invasiveness was measured by an in vitro Matrigel invasion assay. RESULTS: CFE significantly suppressed MMP-9 expression and activation in a dose-dependent manner. Furthermore, CFE attenuated the TPA-induced activation of AP-1. CONCLUSION: The results indicated that the inhibitory effects of CFE against TPA-induced MMP-9 expression and MCF-7 cell invasion were dependent on the protein kinase C δ/p38/c-Jun N-terminal kinase/AP-1 pathway. Therefore, CFE could restrict breast cancer invasiveness owing to its ability to inhibit MMP-9 activity.
Asia
;
Blotting, Western
;
Breast Neoplasms
;
Cell Survival
;
Croton
;
DNA
;
Ethanol
;
Fruit
;
In Vitro Techniques
;
Matrix Metalloproteinase 9*
;
MCF-7 Cells*
;
Neoplasm Invasiveness
;
Protein Kinase C
;
Real-Time Polymerase Chain Reaction
;
Transcription Factor AP-1*
8.The Correlation between Body Mass Index and Routine Parameters in Men Over Fifty.
Deok Ha SEO ; Sol YOON ; Jae Hwi CHOI ; Jungmo DO ; Sin Woo LEE ; Chunwoo LEE ; Seong Uk JEH ; See Min CHOI ; Sung Chul KAM ; Jeong Seok HWA ; Ky Hyun CHUNG ; Sung Won KWON ; Sae Chul KIM ; Dong Soo PARK ; Jae Mann SONG ; Kyung Seop LEE ; Jae Seog HYUN
The World Journal of Men's Health 2017;35(3):178-185
PURPOSE: This study aimed to investigate the relationships between body mass index (BMI) and prostate-specific antigen (PSA) levels, international prostate symptom score (IPSS), quality of life (QoL), and prostate volume (PV). MATERIALS AND METHODS: Height, weight, PSA levels, PV, and IPSS were analyzed in 15,435 patients who underwent a prostate examination between 2001 and 2014. Patients aged <50 years or with a PSA level ≥10 ng/mL were excluded. The relationships between BMI and PSA, IPSS, QoL, and PV were analyzed by a scatter plot, one-way analysis of variance, and the Pearson correlation coefficient. RESULTS: The mean age was 71.95±7.63 years, the mean BMI was 23.59±3.08 kg/m2, the mean PSA level was 1.45±1.45 ng/mL, the mean IPSS was 15.53±8.31, the mean QoL score was 3.48±1.25, and the mean PV was 29.72±14.02 mL. PSA, IPSS, and QoL showed a tendency to decrease with increasing BMI, and there were statistically significant differences for each parameter (p≤0.001). PV showed a significant tendency to increase with BMI (p < 0.001). In the correlation analysis, BMI showed a statistically significant correlation (p < 0.001) with PSA, IPSS, and QoL, although the correlations were very weak. In contrast, BMI showed a significant correlation with PV (p < 0.001), with a meaningful Pearson correlation coefficient of 0.124. CONCLUSIONS: Higher BMI was associated with lower PSA levels and higher IPSS and QoL scores. Meanwhile, PV increased with BMI. Although obese individuals had a greater PV, obesity did not aggravate lower urinary tract symptoms.
Body Mass Index*
;
Humans
;
Lower Urinary Tract Symptoms
;
Male
;
Obesity
;
Prostate
;
Prostate-Specific Antigen
;
Prostatic Hyperplasia
;
Quality of Life
9.Current status of and strategies for hepatitis C control in South Korea.
Beom Kyung KIM ; Eun Sun JANG ; Jeong Han KIM ; Soo Young PARK ; Song Vogue AHN ; Hyung Joon KIM ; Do Young KIM
Clinical and Molecular Hepatology 2017;23(3):212-218
Chronic hepatitis C (CHC) is caused by hepatitis C virus (HCV) infection. HCV infection causes acute hepatitis, and the majority of those infected progress to chronic hepatitis, and some of them develop cirrhosis and hepatocellular carcinoma. Transmission of HCV is parenteral, and the major transmission routes include drug abuse, insecure injections or medical procedures, contaminated syringes or needles, sexual contact with an HCV-infected person, vertical infection of newborns by infected mothers, the transfusion of blood or blood products contaminated with viruses, and organ transplants. As no vaccine against HCV is available, HCV management involves blocking routes of transmission transmission, screening for HCV infection, and protecting liver disease progression by treatment. Highly potent oral direct antiviral agents are now available. Therefore, early detection through nation-wide screening program and appropriate treatment should be implemented to improve the quality of life of patients with HCV. Furthermore, for the effective HCV control in South Korea, The organization of an ‘integrated national viral hepatitis control system’ is desirable.
Antiviral Agents
;
Carcinoma, Hepatocellular
;
Fibrosis
;
Hepacivirus
;
Hepatitis C*
;
Hepatitis C, Chronic
;
Hepatitis*
;
Hepatitis, Chronic
;
Humans
;
Infant, Newborn
;
Korea*
;
Liver Diseases
;
Mass Screening
;
Mothers
;
Needles
;
Quality of Life
;
Substance-Related Disorders
;
Syringes
;
Transplants
10.Secular Trends for Diagnostic Motives and Environmental Risk Factors in Thyroid Cancer Using Questionnaire Survey.
Hana KIM ; Yul HWANGBO ; Sung Hye KONG ; Young Shin SONG ; Min Joo KIM ; Sun Wook CHO ; You Jin LEE ; Ka Hee YI ; Do Joon PARK ; Eun Kyung LEE ; Young Joo PARK
International Journal of Thyroidology 2017;10(2):82-88
BACKGROUND AND OBJECTIVES: We analyzed the clinicopathologic differences of thyroid cancer by diagnosis periods, diagnostic motives, residence history and clinical risk factors in thyroid cancer patients. MATERIALS AND METHODS: Total 1599 thyroid cancer patients who answered the questionnaires about family history of thyroid cancer, residence history including duration of residence and location were enrolled from two hospitals, Seoul National University Hospital and National Cancer Center in Korea. Demographics and environmental information were collected via questionnaires and clinical data were reviewed via electronic medical records. RESULTS: More thyroid cancer has been diagnosed in 2011 to 2013 by screening test without specific symptom than before 1990. The size of cancer at diagnosis was significantly smaller and multifocal tumor was more frequently found in 2011 to 2013 than before 1990 as well. The tumors of obese or overweight patients tended to harbor extrathyroidal extension and lymph node metastasis than normal weight subjects with statistical significance. However, there were no differences in clinicopathologic characteristics according to residence and smoking history. CONCLUSION: In this study, there were some different clinicopathologic characteristics according to the diagnosis era, diagnostic motives, family history of thyroid cancer and body mass index.
Body Mass Index
;
Demography
;
Diagnosis
;
Electronic Health Records
;
Humans
;
Korea
;
Lymph Nodes
;
Mass Screening
;
Neoplasm Metastasis
;
Overweight
;
Risk Factors*
;
Seoul
;
Smoke
;
Smoking
;
Thyroid Gland*
;
Thyroid Neoplasms*

Result Analysis
Print
Save
E-mail